Kathleen Jaeger resigns as head of US generics group
This article was originally published in Scrip
Kathleen Jaeger, the president and CEO of the US generics trade group GPhA, has resigned from her post, held since 2002, less than two weeks after the group's largest member, Teva Pharmaceutical Industries, announced it was pulling out of the association owing to objections over the group's current structure (scripnews.com, 26 April 2010).
You may also be interested in...
Unlike AMAG's Makena, nearly all the products that have seen their accelerated approvals pulled have left the market quietly, our infographic shows.
CBER’s Peter Marks says agency assesses the importance of durability of effect differently for a gene therapy that treats a disease that has no other available therapies versus a condition for which there are multiple approved treatments. Marks’ comments shed more light on the complete response letter for BioMarin’s hemophilia gene therapy Roctavian.
Communication and education on samidorphan’s opioid antagonistic effects should focus on health care providers that prescribe opioids as well as psychiatrists that prescribe olanzapine, advisory committee says in endorsing the safety and efficacy of ALKS 3831.